Anti-IgE therapy for allergic bronchopulmonary aspergillosis

Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma. Some cases are resistant to treatment, even with regular use of antiasthmatic drugs and antifungal agents. The diagnosis of ABPA was made in a 40-year-old patient with ABPA according to the Rosenberg-Patterson criteria. Sympt...

Full description

Saved in:
Bibliographic Details
Published in:Journal of microbiology, immunology and infection immunology and infection, 2016-06, Vol.49 (3), p.459-463
Main Authors: Homma, Tetsuya, Kurokawa, Masatsugu, Matsukura, Satoshi, Yamaguchi, Munehiro, Adachi, Mitsuru
Format: Article
Language:English
Subjects:
Adolescent
Adult
Allergic bronchopulmonary aspergillosis
Anti-Asthmatic Agents - therapeutic use
Antibodies, Anti-Idiotypic - therapeutic use
Antifungal Agents - therapeutic use
Aspergillosis, Allergic Bronchopulmonary - drug therapy
Aspergillosis, Allergic Bronchopulmonary - immunology
Aspergillosis, Allergic Bronchopulmonary - microbiology
Aspergillus
Aspergillus fumigatus - drug effects
Aspergillus fumigatus - immunology
Female
Humans
IgE
Immunotherapy - methods
Infectious Disease
Male
Medical Education
Middle Aged
Omalizumab
Omalizumab - therapeutic use
Prednisolone
Severe asthma
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma. Some cases are resistant to treatment, even with regular use of antiasthmatic drugs and antifungal agents. The diagnosis of ABPA was made in a 40-year-old patient with ABPA according to the Rosenberg-Patterson criteria. Symptoms were not controlled despite regular use of antiasthmatic drugs, daily systemic steroids, and antifungal agents. Omalizumab, administered in an attempt to stabilize these uncontrolled symptoms, was effective with no adverse events. Our experience suggests omalizumab is a potential candidate drug for controlling steroid-dependent ABPA.
ISSN:1684-1182
1995-9133
DOI:10.1016/j.jmii.2013.10.003